Lineage Cell Therapeutics to Announce Q1 2024 Financials and Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc., headquartered in CARLSBAD, Calif., is a clinical-stage biotechnology firm focusing on developing allogeneic cell therapies to tackle unmet medical needs. The company is set to announce its financial and operating results for the first quarter of 2024 on May 9, 2024, after the U.S. financial markets close. To discuss these results and offer a business update, Lineage's management will hold a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day.

To join the conference call, interested individuals from the U.S. and Canada can dial (800) 715-9871 and request the “Lineage Cell Therapeutics Call.” Additionally, a live webcast will be accessible on the Investors section of Lineage's website. The webcast replay will be available for 30 days on the company’s website, and a telephone replay will be accessible until May 15, 2024, by dialing (800) 770-2030 and entering conference ID number 1330332.

Lineage Cell Therapeutics specializes in creating novel "off-the-shelf" cell therapies, leveraging its proprietary cell-based technology and development capabilities. The company's approach involves the design, development, manufacturing, and testing of specialized human cells, which mimic the functions of naturally occurring cells in the human body. By applying directed differentiation protocols to well-characterized, self-renewing pluripotent cell lines, Lineage generates cells possessing specific developmental lineage characteristics. These cells can be transplanted into patients to replace or support dysfunctional or absent cells, potentially restoring or enhancing the patient's functional activity.

The company's neuroscience-focused pipeline includes several key programs:

1. OpRegen: This retinal pigment epithelial cell therapy is in Phase 2a development for geographic atrophy secondary to age-related macular degeneration. It is being developed under a global collaboration with Roche and Genentech, a member of the Roche Group.

2. OPC1: Designed as an oligodendrocyte progenitor cell therapy, OPC1 is in Phase 1/2a development aimed at treating spinal cord injuries.

3. ANP1: This auditory neuronal progenitor cell therapy holds potential for treating auditory neuropathy.

4. PNC1: A photoreceptor neural cell therapy, PNC1 is intended to address vision loss caused by photoreceptor dysfunction or damage.

5. RND1: In collaboration with Eterna Therapeutics Inc., Lineage is developing RND1, a novel hypoimmune induced pluripotent stem cell line.

Lineage's innovative approach and dedication to addressing severe medical conditions through advanced cell therapies position it as a pioneer in the biotechnology sector.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!